New NCL Assessment of Sona’s GNR Technology Highlights Process Improvement Success
Halifax, Nova Scotia — (Newsfile Corp. – June 8, 2023) – Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”). In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels, this assessment included an analysis of the surfactant residue present following the chemical reaction necessary for the manufacture of Sona’s proprietary gold nanorods. The assessment shows that the continued improvements in Sona’s manufacturing process for gold nanorods have resulted in a significant reduction in free surfactant levels in nanorod dispersions, with the average dropping from 230.7 ug/mL in prior assessed batches to 34.6 ug/mL in the batches following the process changes. As with the NCL’s prior assessments of earlier batches of Sona’s gold nanorods, this new assessment did not detect any endotoxins or microbial contamination.
“Sona’s laboratory has undertaken a manufacturing enhancement program in preparation for the production of the gold nanorods necessary for our anticipated pre-clinical trials and studies. This program has resulted in improved yields and reduced surfactant levels with no loss in stability or biocompatibility, as evidenced by these additional excellent NCL assessment results which we were very pleased to receive”, Sona’s CEO, David Regan, commented.
.
